Characteristics of patients with breast cancer, Denmark, 1990–2017
| Total | 84 972 (100) |
| Median follow-up time, years (25th–75th percentiles) | 7.4 (3.5–12.9) |
| Median age, years (25th–75th percentiles) | 61.3 (51.7–70.0) |
| Age group | |
| 18–49 years | 17 220 (20.3) |
| 50–59 years | 22 107 (26.0) |
| 60–69 years | 24 535 (28.9) |
| ≥70 years | 21 110 (24.8) |
| Calendar period | |
| 1990–2006 | 46 889 (55.2) |
| 2007–2017 | 38 083 (44.8) |
| Breast cancer stage | |
| Localised | 48 960 (57.6) |
| Regional spread | 36 012 (42.4) |
| Oestrogen receptor status* | |
| Positive | 42 192 (59.8) |
| Negative | 9705 (13.8) |
| Unknown | 18 612 (26.4) |
| HER2 receptor status* | |
| Positive | 1944 (2.8) |
| Negative | 11 711 (16.6) |
| Unknown | 56 854 (80.6) |
| Treatment within the first year after diagnosis | |
| Radiotherapy | 43 722 (51.5) |
| Chemotherapy | 27 117 (31.9) |
| Tamoxifen therapy | 14 789 (17.4) |
| Aromatase inhibitor treatment† | 594 (1.6) |
| Lumpectomy* | 40 833 (57.9) |
| Mastectomy* | 32 229 (45.7) |
| Charlson Comorbidity Index score | |
| Low (score=0) | 68 812 (81.0) |
| Moderate (score=1–2) | 14 317 (16.9) |
| Severe (score >2) | 1843 (2.2) |
Data are numbers (%) unless otherwise specified.
*Restricted to 1996 onwards due to limitations in data availability.
†Restricted to 2007 onwards due to limited registration.
HER2, human epidermal growth factor receptor 2.